128 related articles for article (PubMed ID: 36929439)
1. Del(1p32): prime time in (ultra) high-risk myeloma.
Khot A
Blood; 2023 Mar; 141(11):1241-1243. PubMed ID: 36929439
[No Abstract] [Full Text] [Related]
2. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
[TBL] [Abstract][Full Text] [Related]
3. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
Schavgoulidze A; Talbot A; Perrot A; Cazaubiel T; Leleu X; Manier S; Buisson L; Mahéo S; Do Souto Ferreira L; Pavageau L; Hulin C; Marolleau JP; Voillat L; Belhadj K; Divoux M; Slama B; Brechignac S; Macro M; Stoppa AM; Sanhes L; Orsini-Piocelle F; Fontan J; Chretien ML; Demarquette H; Mohty M; Avet-Loiseau H; Corre J
Blood; 2023 Mar; 141(11):1308-1315. PubMed ID: 36375118
[TBL] [Abstract][Full Text] [Related]
4. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients.
Hebraud B; Leleu X; Lauwers-Cances V; Roussel M; Caillot D; Marit G; Karlin L; Hulin C; Gentil C; Guilhot F; Garderet L; Lamy T; Brechignac S; Pegourie B; Jaubert J; Dib M; Stoppa AM; Sebban C; Fohrer C; Fontan J; Fruchart C; Macro M; Orsini-Piocelle F; Lepeu G; Sohn C; Corre J; Facon T; Moreau P; Attal M; Avet-Loiseau H
Leukemia; 2014 Mar; 28(3):675-9. PubMed ID: 23892719
[TBL] [Abstract][Full Text] [Related]
5. del(1p32), a powerful prognostic factor in myeloma.
Blood; 2023 Mar; 141(11):1367. PubMed ID: 36929429
[No Abstract] [Full Text] [Related]
6. [Correlation between chromosome 13q14 deletion and 1q abnormality in multiple myeloma].
Chen LJ; Li JY; Zhu Y; Wang XW; Qiu HR; Yang RF; Xu W; Xu JR; Lu H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Feb; 26(1):102-5. PubMed ID: 19199264
[TBL] [Abstract][Full Text] [Related]
7. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.
Boyd KD; Ross FM; Walker BA; Wardell CP; Tapper WJ; Chiecchio L; Dagrada G; Konn ZJ; Gregory WM; Jackson GH; Child JA; Davies FE; Morgan GJ;
Clin Cancer Res; 2011 Dec; 17(24):7776-84. PubMed ID: 21994415
[TBL] [Abstract][Full Text] [Related]
8. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.
Hebraud B; Magrangeas F; Cleynen A; Lauwers-Cances V; Chretien ML; Hulin C; Leleu X; Yon E; Marit G; Karlin L; Roussel M; Stoppa AM; Belhadj K; Voillat L; Garderet L; Macro M; Caillot D; Mohty M; Facon T; Moreau P; Attal M; Munshi N; Corre J; Minvielle S; Avet-Loiseau H
Blood; 2015 Mar; 125(13):2095-100. PubMed ID: 25636340
[TBL] [Abstract][Full Text] [Related]
9. Chromosome 13 deletion in myeloma.
Shaughnessy J; Barlogie B
Curr Top Microbiol Immunol; 1999; 246():199-203. PubMed ID: 10396057
[No Abstract] [Full Text] [Related]
10. [Detection of deletion of the long arm of chromosome 13 and translocation of immunoglobulin heavy chain gene by interphase fluorescence in situ hybridization in patients with multiple myeloma].
Sun WL; Wu YJ; Li H; Wang X; Zhuang JL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):485-90. PubMed ID: 18795626
[TBL] [Abstract][Full Text] [Related]
11. [Application of fluorescence in-situ hybridization technique in multiple myeloma].
Zhao Y; Zheng D; Li J; Zhu WT
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 38(5):459-64. PubMed ID: 19830857
[TBL] [Abstract][Full Text] [Related]
12. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.
Grzasko N; Hajek R; Hus M; Chocholska S; Morawska M; Giannopoulos K; Czarnocki K; Druzd-Sitek A; Pienkowska-Grela B; Rygier J; Usnarska-Zubkiewicz L; Dytfeld D; Kubicki T; Jurczyszyn A; Korpysz M; Dmoszynska A
Leuk Lymphoma; 2017 Sep; 58(9):1-15. PubMed ID: 28092996
[TBL] [Abstract][Full Text] [Related]
13. [Detection of del(17p13) among newly diagnosed multiple myeloma cases using cytoplasmic light chain immunofluorescence combined with FISH and its clinical significance].
Lu X; Chen L; Shi Q; Qiu H; Li J; Guo R
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Oct; 37(10):1087-1091. PubMed ID: 32924107
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetics of multiple myeloma.
Trcić RL; Skelin IK; Sustercić D; Planinc-Peraica A; Ajduković R; Haris V; Kusec R; Begović D
Coll Antropol; 2010 Mar; 34(1):41-4. PubMed ID: 20432732
[TBL] [Abstract][Full Text] [Related]
16. [Investigation of the molecular changes in patients with multiple myeloma by fluorescence in situ hybridization].
Yang RF; Li CM; Chen LJ; Qiu HR; Yang H; Liu P; Xu JR; Li JY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Oct; 27(5):567-70. PubMed ID: 20931539
[TBL] [Abstract][Full Text] [Related]
17. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma.
Mohan M; Gong Z; Ashby TC; Al Hadidi S; Thanendrarajan S; Schinke C; Alapat D; Shaughnessy JD; Zhan F; van Rhee F; Sawyer JR; Tian E; Zangari M
Cancer; 2023 Aug; 129(16):2491-2498. PubMed ID: 37282609
[TBL] [Abstract][Full Text] [Related]
18. Impact of acquired del(17p) in multiple myeloma.
Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
Blood Adv; 2019 Jul; 3(13):1930-1938. PubMed ID: 31248884
[TBL] [Abstract][Full Text] [Related]
19. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
[TBL] [Abstract][Full Text] [Related]
20. Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma.
Kaufmann H; Krömer E; Nösslinger T; Weltermann A; Ackermann J; Reisner R; Bernhart M; Drach J
Eur J Haematol; 2003 Sep; 71(3):179-83. PubMed ID: 12930318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
